Timothy Yap, MBBS, Ph.D., MD Anderson Cancer Center, FDA Approval of Pembrolizumab The 1st approval of a drug that is tumor agnostic at AACR 2018.
FDA Approval of Pembrolizumab The 1st approval of a drug that is tumor agnostic
Timothy Yap, MBBS, Ph.D., MD Anderson Cancer Center, FDA Approval of Pembrolizumab The 1st approval of a drug that is tumor agnostic at AACR 2018.